Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jul 29, 2021 9:52pm
173 Views
Post# 33630409

RE:Short volume

RE:Short volume His original $12 price target was clearly too aggressive at the time but indicated he was angling for the lead on the eventual fundraising. His $3 current target is his "you did not give me the lead on either of the deals after I did my part to get it" price target. The company had only gotten better over the time he covered it (moving from HIV NASH to and FDA/EMA supported phase III general NASH program and making significant strides in fast-tracked cancer while sales of the legacy drugs moved marginally higher. The just has not been enough bad happening over that time to justify the massive price target reduction. Indeed, two rather incredible things happened in THTX's pipeline during that time.
scarlet1967 wrote:

As per fintel 53k shares were shorted today which equals about 8% short volume.

So Mr. NASH managed to spook investors to sell almost 400k shares resulting in over 4% decline in SP so yes let’s feel sorry for him since he can’t pick up his next cheque from the company so he can book a holiday working on his tan, never mind his PT goes from $12 to $3 in less than 18 months based on what ever bogus analysis.



<< Previous
Bullboard Posts
Next >>